ReviewClinical and experimental immunology2007
Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.
Review in Clinical and experimental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.Experimental hematology & oncology · 2018Article
- Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.Blood advances · 2017Article
- Peptide vaccine therapy for leukemia.International journal of hematology · 2011Review
- Do we have to kill the last CML cell?Leukemia · 2011Review
- Immunotherapy prospects for acute myeloid leukaemia.Clinical and experimental immunology · 2010Review
- Relapse after allogeneic stem cell transplantation.Expert review of hematology · 2010Review
- From bench to bedside: the growing use of translational research in cancer medicine.American journal of translational research · 2010Article
- Dendritic Cells Loaded with Tumor Antigens and a Dual Immunostimulatory and Anti-Interleukin 10-Specific Small Interference RNA Prime T Lymphocytes against Leukemic Cells.Translational oncology · 2009Article
- Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Article
- Review
- Article
- Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.Leukemia · 2008Article
- Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.Current hematologic malignancy reports · 2008Article
- T cell therapy in allogeneic stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The graft-versus-leukaemia (GVL) effect following allogeneic stem cell transplantation is clear evidence that T lymphocytes can control and eliminate myeloid leukaemias. The successful identification of a range of leukaemia specific antigens (LSA) in recent years has stimulated efforts to induce leukaemia specific T cell responses to these antigens with peptide vaccines. An ideal LSA should be restricted in its expression to leukaemia including progenitor cells, intrinsically connected with the leukaemic phenotype, and capable of inducing strong cytotoxic T cell responses to the leukaemia. Peptides from three well-characterized LSA, the breakpoint cluster region-abelson (BCR-ABL) fusion protein of chronic myelogenous leukaemia, proteinase-3 and Wilms tumour 1 protein, serve as the basis for several clinical trials using peptide and adjuvants to treat patients with a variety of myeloid malignancies. Preliminary results from these studies indicate that these peptides induce immune responses which can translate into clinical responses which include complete remissions from leukaemia. These promising early results point the way to optimizing the administration of peptide vaccines and suggest ways of combining vaccination with allogeneic stem cell transplantation to boost GVL effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.